Offers Claimed: 90
Downloaded Today: 196
USARx offers the following ways to purchase this medication. Choose the Best option for you!
Yes99% of Medicare Part D and Medicare Advantage plans cover this drug.
It depends. Which coverage stage are you in? Click on a tab below…
FREE – $59
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your valsartan prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Commonly reported side effects of valsartan include: dizziness and increased serum potassium. Other side effects include: hypotension. See below for a comprehensive list of adverse effects.For the Consumer
Applies to valsartan: oral tablet
Oral route (Capsule; Tablet; Solution)
When pregnancy is detected, discontinue valsartan as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Along with its needed effects, valsartan may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking valsartan:
Incidence not known
Some side effects of valsartan may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
For Healthcare Professionals
Applies to valsartan: oral capsule, oral tabletNervous system
Very common (10% or more): Headache (up to 14%), dizziness (up to 14%)
Common (1% to 10%): Dizziness
Uncommon (0.1% to 1%): VertigoRespiratory
Common (1% to 10%): Cough
Uncommon (0.1% to 1%): DyspneaHypersensitivity
A 71-year-old woman experienced an acute onset of angioedema and a photosensitive pruritic rash after 3 months of valsartan therapy. Her symptoms dissipated and the rash resolved after treatment with subcutaneous epinephrine, intravenous methylprednisolone, diphenhydramine, and emollient cream.
A unique case of dose-dependent, valsartan-induced angioedema has been reported. Two hours after initiating a dose increase (160 to 320 mg/day) of valsartan, a patient developed angioedema (i.e., swelling of lips and tongue). Symptoms resolved following a reduction in dose to the original dosage of 160 mg/day.
Very rare (less than 0.01%): AngioedemaCardiovascular
Common (1% to 10%): Symptomatic hypotension in 5.5% of heart failure patients in clinical trials
Rare (less than 0.1%): Palpitations, chest pain
Frequency not reported: Dizziness related to orthostatic hypotension
Postmarketing reports: Heart failureMetabolic
Common (1% to 10%): Hyperkalemia, hyponatremiaRenal
Frequency not reported: Impaired renal function, increases in serum creatinine concentrations, blood urea nitrogen, and potassium
Postmarketing reports: Renal failureDermatologic
Rare (less than 0.1%): Pruritus, rash, alopecia
Postmarketing reports: Bullous dermatitisGastrointestinal
Uncommon (0.1% to 1%): Diarrhea, constipation, dry mouth, dyspepsia, anorexia, nausea, vomiting, flatulence
Postmarketing reports: Taste disturbance (i.e., altered sensitivity of basic tastes) has been reported following repeated dosingMusculoskeletal
Common (1% to 10%): Back pain, muscle cramps, myalgias
Very rare (less than 0.01%): RhabdomyolysisPsychiatric
Frequency not reported: Anxiety, insomnia, paresthesias, somnolenceGenitourinary
Very rare (less than 0.01%): ImpotenceHematologic
Uncommon (0.1% to 1%): Hematocrit decreased, hemoglobin decreased, neutropenia
Postmarketing reports: Thrombocytopenia, vasculitisHepatic
Valsartan-associated hepatotoxicity in a patient with hepatitis B surface antigen (HBs-Ag) positivity (without signs and symptoms) has been reported. After 1 month of treatment with valsartan, this patient developed pruritic erythematous skin changes, nausea, jaundice, right subcostal abdominal pain, elevated liver enzymes, and mild hepatomegaly. Signs and symptoms of hepatotoxicity resolved within 2 to 3 weeks following discontinuation of valsartan and the patient remained asymptomatic after 6 months of follow-up.
Very rare (less than 0.01%): Hepatitis
Frequency not reported: Hepatic enzymes increased
December 1, 2020
October 2, 2020
October 2, 2020
June 18, 2020
February 12, 2020
March 31, 2021